EIM
EIGR

Essex Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Essex Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-862
Closed -$263K – 519
2018
Q4 		$263K Sell
862
-859
-50% -$278K 0.04% 307
2018
Q3 		$619K Buy
+1,721
New +$589K 0.07% 279

Other funds holding EIGR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Essex Investment Management's EIGR Position: Q1 2019 in Review

Essex Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2019, closing a stake of 862 shares — an estimated $263K sold.

Essex Investment Management first reported a position in EIGR in Q3 2018 and held it in 2 quarters. The position peaked at $619K in Q3 2018. 63 funds tracked by Wall St. Rank hold EIGR as of Q1 2019.

  • Essex Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Essex Investment Management sold 862 Eiger BioPharmaceuticals, Inc. shares in Q1 2019, an estimated $263K.
  • Essex Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Essex Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $619K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.